Suzhou Ribo Life Science is a China-based biotechnology company focused on RNA interference (RNAi) therapies and oligonucleotide drug development. It has established an end-to-end, internally controlled platform for oligonucleotide drug discovery and development, including liver-targeted delivery technologies and chemical modification platforms to advance multiple product candidates. The company concentrates on cardiovascular, metabolic, liver, kidney, and rare diseases, with a global expansion strategy and a pipeline aimed at progressing RNAi therapeutics from early research to clinical use.
No recent news for this company.
No recent deals for this company.